Get started
Author

Sandra Sánchez‐Gregorio

Observed names: Sandra Sanchez-Gregorio, Sandra Sanchez‐Gregorio, Sandra Sánchez-Gregorio
Observed institutions: Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad de Navarra
ORCID: 0000-0003-1797-3397
Observed ORCID: 0000-0003-1797-3397
OpenAlex ID: A5075446529
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL ‐8
2021 · Carlos E de Andrea, María Carmen Ochoa, et al. · The Journal of Pathology · 111
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
2021 · Itziar Otano, Arantza Azpilikueta, et al. · Nature Communications · 86
PDF
CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma
2018 · Rafael Samaniego, Alejandra Gutiérrez-González, et al. · Cancer Immunology Research · 80
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
2024 · Alvaro Teijeira, Saray Garasa, et al. · Clinical Cancer Research · 32
Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
2023 · Ignacio Melero, Maria C Ochoa, et al. · EMBO Molecular Medicine · 27
PDF
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
2022 · Assunta Cirella, Elixabet Bolaños, et al. · Cancer Immunology Research · 26
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
2023 · Maria Carmen Ochoa, Sandra Sanchez-Gregorio, et al. · Cell Reports Medicine · 24
Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
2023 · Assunta Cirella, Elixabet Bolaños, et al. · Molecular Therapy — Nucleic Acids · 10
A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
2025 · Maria Alsina, Guillermo Villacampa, et al. · Clinical Cancer Research · 8
PDF
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
2024 · Iñaki Eguren-Santamaría, Inmaculada Rodríguez, et al. · OncoImmunology · 6
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al. · Clinical Cancer Research · 5
Figure S5 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Table S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Table S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Figure S2 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Table S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Figure S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Data from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Figure S3 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Supplementary Appendix from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Table S1 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Figure S4 from Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab
2026 · Miguel F. Sanmamed, Carlos E. de Andrea, et al.
Supplementary Data from Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
2025 · Assunta Cirella, Elixabet Bolaños, et al.
531 A multi-cohort phase 1-2 clinical trial shows safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4–1BB) mAb urelumab in combination with nivolumab
2025 · Miguel F Sanmamed, Carlos E De Andrea, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Methodology S1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
2025 · Maria Alsina, Guillermo Villacampa, et al.
Works count: 65
Citation count: 415
H-index: 8
I10-index: 8
Year
Topic
Type